Jieyu Zou has been promoted to managing director at Lilly Asia Ventures (LAV), the venture capital firm spun out of pharmaceutical company Eli Lilly.
Based in Shanghai, China, Zou has worked her way up from investment manager since joining LAV in May 2015.
She is on the boards of Gracell, Transcenta and Virtue DX.
Her earlier deals have included Geneception, CARsgen, Edigene, Tmunity and Passage Bio in new modality therapeutics, Sansure in molecular diagnostics and Avedro, which was acquired in November 2019 for about $500m by Glaukos after an earlier flotation.
LAV has been raising its latest funds from external investors.
Photo courtesy of LinkedIn.
